Active surveillance of ambulatory and hospitalized children 2–23 months old in Cordoba, Argentina for invasive pneumococcal disease and radiographically confirmed “obvious” pneumonia revealed annual incidences of 206.8 and 2422 cases, respectively, per 100,000 children. The invasive pneumococcal disease incidence was substantially higher than those previously reported from Latin America and Europe.
From the *Centro de Desarrollo de Proyectos Avanzados, Cordoba, Argentina; †GlaxoSmithKline Biologicals, Buenos Aires, Argentina; and ‡GlaxoSmithKline Biologicals, Rixensart, Belgium
Accepted for publication November 8, 2005.
Supported by GlaxoSmithKline Biologicals. Dr M. Tregnaghi has served as a consultant to and has received research grants from GlaxoSmithKline Biologicals, which has a pneumococcal conjugate vaccine program. Drs Caballos, Ussher and P. Tregnaghi are employed by CDEPAP, which has received support from GlaxoSmithKline Biologicals.
E-mail email@example.com. Reprints not available.